Patient characteristics by cohort
| Characteristic . | Cohort with MBL (n = 219) . | Cohort with CLL (n = 226) . |
|---|---|---|
| Age at diagnosis, y | ||
| Median | 65.89 | 63.06 |
| Range | (44.15-86.38) | (37.39-90.92) |
| Sex | ||
| Female | 88 (40.2) | 63 (27.9) |
| Male | 131 (59.8) | 163 (72.1) |
| Rai stage | ||
| Missing | 0 | 1 |
| 0 | 219 (100.0) | 143 (63.6) |
| I | 0 (0.0) | 53 (23.6) |
| II | 0 (0.0) | 16 (7.1) |
| III | 0 (0.0) | 2 (0.9) |
| IV | 0 (0.0) | 11 (4.9) |
| β-2-Microglobulin, μg/mL | ||
| Missing | 9 | 4 |
| Median | 2.06 | 2.44 |
| Range | (1.00-21.50) | (0.20-14.50) |
| IGHVmutation status | ||
| Missing | 21 | 2 |
| Mutated | 150 (75.8) | 114 (50.9) |
| Unmutated | 48 (24.2) | 110 (49.1) |
| High-risk FISH: (11q, 17p) vs other | ||
| Missing | 10 | 7 |
| FISH: none detected, 13q, trisomy 12 | 201 (96.2) | 190 (86.8) |
| FISH: 11q, 17p | 8 (3.8) | 29 (13.2) |
| CLL-IPI risk | ||
| Missing | 31 | 7 |
| Low risk (0-1) | 121 (64.4) | 83 (37.9) |
| Intermediate risk (2-3) | 48 (25.5) | 83 (37.9) |
| High risk (4-6) | 18 (9.6) | 42 (19.2) |
| Very high risk (7-10) | 1 (0.5) | 11 (5.0) |
| Epitype | ||
| Missing | 0 | 3 |
| HP | 142 (64.8) | 92 (41.3) |
| IP | 42 (19.2) | 45 (20.2) |
| LP | 35 (16.0) | 86 (38.6) |
| ELCLV3-21 | ||
| High risk | 43 (19.6) | 102 (45.1) |
| Low risk | 176 (80.4) | 124 (54.9) |
| Characteristic . | Cohort with MBL (n = 219) . | Cohort with CLL (n = 226) . |
|---|---|---|
| Age at diagnosis, y | ||
| Median | 65.89 | 63.06 |
| Range | (44.15-86.38) | (37.39-90.92) |
| Sex | ||
| Female | 88 (40.2) | 63 (27.9) |
| Male | 131 (59.8) | 163 (72.1) |
| Rai stage | ||
| Missing | 0 | 1 |
| 0 | 219 (100.0) | 143 (63.6) |
| I | 0 (0.0) | 53 (23.6) |
| II | 0 (0.0) | 16 (7.1) |
| III | 0 (0.0) | 2 (0.9) |
| IV | 0 (0.0) | 11 (4.9) |
| β-2-Microglobulin, μg/mL | ||
| Missing | 9 | 4 |
| Median | 2.06 | 2.44 |
| Range | (1.00-21.50) | (0.20-14.50) |
| IGHVmutation status | ||
| Missing | 21 | 2 |
| Mutated | 150 (75.8) | 114 (50.9) |
| Unmutated | 48 (24.2) | 110 (49.1) |
| High-risk FISH: (11q, 17p) vs other | ||
| Missing | 10 | 7 |
| FISH: none detected, 13q, trisomy 12 | 201 (96.2) | 190 (86.8) |
| FISH: 11q, 17p | 8 (3.8) | 29 (13.2) |
| CLL-IPI risk | ||
| Missing | 31 | 7 |
| Low risk (0-1) | 121 (64.4) | 83 (37.9) |
| Intermediate risk (2-3) | 48 (25.5) | 83 (37.9) |
| High risk (4-6) | 18 (9.6) | 42 (19.2) |
| Very high risk (7-10) | 1 (0.5) | 11 (5.0) |
| Epitype | ||
| Missing | 0 | 3 |
| HP | 142 (64.8) | 92 (41.3) |
| IP | 42 (19.2) | 45 (20.2) |
| LP | 35 (16.0) | 86 (38.6) |
| ELCLV3-21 | ||
| High risk | 43 (19.6) | 102 (45.1) |
| Low risk | 176 (80.4) | 124 (54.9) |
Data are given as number (percentage) unless otherwise indicated.
FISH, fluorescence in situ hybridization.